author-photo

Jason B. Cross

Cubist Pharmaceuticals

23

Papers

543

Citations

Citation Trend

Filter By

Papers (17) Sort By

Journal Conference Others

Erratum: Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity (Cancer Cell (2019) 36(4) (444–457.e7), (S1535610819303848), (10.1016/j.ccell.2019.09.001))

2020 Cancer Cell
Show All
- Source
- Cite
- Save
Citations (3)
Abstract 3277: IACS-9779, a development candidate that inhibits 2,3-dioxygenase (IDO) activity by blocking heme incorporation into IDO apoenzyme

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
P1.14-08 Activity of Poziotinib and Other 2nd-Gen Quinazoline EGFR TKIs in Atypical Exon18 and Acquired Osimertinib Resistance Mutants

2019 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Structure-based discovery of LpxC inhibitors

2017 Bioorganic & Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (11)
Crystal structure of Pseudomonas aeruginosa LpxC complexed with inhibitor

2017
Show All
- Source
- Cite
- Save
Citations (0)
Fragment-based discovery of DNA gyrase inhibitors targeting the ATPase subunit of GyrB

2016 Bioorganic & Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (23)
Discovery of Azaindole Ureas as a Novel Class of Bacterial Gyrase B Inhibitors.

2015 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (16)
Biarylsulfonamide CCR9 inhibitors for inflammatory bowel disease.

2015 Bioorganic & Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (8)
Crystal structure of the ATP binding domain of S. aureus GyrB complexed with a fragment

2015
Show All
- Source
- Cite
- Save
Citations (0)
Inhibiteurs de la 1,3,4-oxadiazole et de la 1,3,4-thiadiazole bêta-lactamase

2013
Show All
- Source
- Cite
- Save
Citations (0)